LOS ANGELES Dec 21 Drug developer
Pharmacyclics Inc PCYC.O said on Friday that the U.S. Food
and Drug Administration turned down its application to market
Xcytrin as a treatment for non-small cell lung cancer which has
spread to the brain.
The company said in a statement that it continues to
believe that Xcytrin is a novel active cancer drug and will
seek a corporate partner to help support future development.
Pharmacyclics said it expects data in the first half of
2008 from three Phase 2 trials evaluating the drug in patients
with advanced relapsed non-small cell lung cancer.
The company had been seeking approval for use of Xcytrin in
combination with whole brain radiation therapy.
(Reporting by Deena Beasley in Los Angeles; Editing by Gary